LEADER 02447nam 2200397 n 450 001 9910765743003321 005 20230223220639.0 010 $a9783038427964 010 $a3038427969 024 8 $a10.3390/books978-3-03842-796-4 035 $a(CKB)5400000000000211 035 $a(NjHacI)995400000000000211 035 $a(ScCtBLL)b2606382-8099-4522-86ae-24b512d9a08e 035 $a(OCoLC)1154208066 035 $a(EXLCZ)995400000000000211 100 $a20230223d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiology and Treatment of Myeloid Leukaemias /$fedited by Geoffrey Brown and Ewa Marcinkowska 210 1$aBasel, Switzerland :$cMDPI,$d2018. 215 $a1 online resource (vi, 190 pages) 330 $aThere has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy. 606 $aCarcinogens 615 0$aCarcinogens. 676 $a616.994071 702 $aMarcinkowska$b Ewa 702 $aBrown$b Geoffrey 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765743003321 996 $aBiology and Treatment of Myeloid Leukaemias$93652641 997 $aUNINA LEADER 01616nam0 22003491i 450 001 UON00465210 005 20231205105141.137 010 $a978-88-689-7013-0 100 $a20160223d2015 |0itac50 ba 101 $aita$aENG 102 $aIT 105 $a|||| ||||| 200 1 $aˆL'‰Africa, l'Oriente Mediterraneo e l'Europa$etradizioni e culture a confronto$fa cura di Paolo Nicelli 210 $aMilano$cBiblioteca Ambrosiana ; Roma$cBulzoni$d2015 215 $axi, 204 p., [10] p. di tav.$cill. $d24 cm 410 1$1001UON00466541$12001 $aAfricana Ambrosiana$fdirettore Pier Francesco Fumagalli$v1 606 $aAfrica$xRelazioni culturali$xStoria$3UONC089371$2FI 606 $aManoscritti$xAfrica$3UONC085002$2FI 606 $aMANOSCRITTI BERBERI$3UONC021968$2FI 620 $aIT$dRoma$3UONL000004 620 $aIT$dMilano$3UONL000005 676 $a303.482604$cRELAZIONI CULTURALI DELL'AFRICA CON L'EUROPA$v21 702 1$aNicelli$bPaolo$3UONV173717 712 $aBiblioteca Ambrosiana$3UONV270581$4650 712 $aBulzoni$3UONV265597$4650 801 $aIT$bSOL$c20250523$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00465210 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI GEN 1098 $eSI 16829 7 1098 951 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$bSI2016299 1J 20160223 996 $aAfrica, l'Oriente Mediterraneo e l'Europa$91398523 997 $aUNIOR